Download PDF
Zeitschrift für Ganzheitliche Tiermedizin 2014; 28(1): 11-18
DOI: 10.1055/s-0033-1360207
Phytotherapie
Sonntag Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Der Einsatz des Mönchspfeffer-Präparats corticosal® zur Behandlung des equinen Cushing-Syndroms (PPID)

The use of chasteberry preparation corticosal® for the treatment of equine Cushingʼs syndrome (PPID)
Zrinjka Hardenberg
,
Heidrun Gehlen
Further Information

Publication History

Publication Date:
18 February 2014 (online)

    Permissions and Reprints All articles of this category

Zusammenfassung

Ziel dieser Studie war die Überprüfung der Wirksamkeit des mönchspfefferhaltigen Präparats corticosal® zur Behandlung des equinen Cushing-Syndroms (PPID). 38 an PPID erkrankte Pferde und Ponys wurden in 3 Versuchsgruppen eingeteilt und erhielten über einen Zeitraum von 6 Monaten entweder corticosal® (Gruppe T1) oder Pergolid zusammen mit corticosal® (Gruppe T2) oder die ersten 3 Monate Pergolid und ein Placebo und die weiteren 3 Monate Pergolid und corticosal® (Gruppe T3). An 3 Untersuchungszeitpunkten wurden die klinische Symptomatik und verschiedene Blutparameter anhand eines festgelegten Score-Systems ermittelt. In Gruppe T1 konnten sowohl zwischen den 1. und 2. Untersuchungszeitpunkten (p = 0,0042) als auch zwischen den 2. und 3. Untersuchungszeitpunkten (p = 0,001) signifikante Unterschiede der klinischen Parameter festgestellt werden. Die klinischen Symptome verbesserten sich – gemessen am klinischen Gesamtscore – signifikant. Anhand der erhobenen Daten konnte ein positiver Effekt des mönchspfefferhaltigen Präparates corticosal® auf die klinische Symptomatik der am Cushing-Syndrom erkrankten Pferde festgestellt werden.

Summary

The objective of this study was to review the effectiveness of corticosal®, a combination preparation from the chasteberry, for the treatment of equine Cushingʼs syndrome (PPID). 38 horses and ponies with PPID were divided into 3 groups and received either corticorsal® (Group T1) or pergolide along with corticorsal® (Group T2) or for the first 3 months pergolide and a placebo and for the other 3 months pergolide and corticorsal® (Group T3). The therapy lasted 6 months. At 3 study points, the clinical presentation and various blood parameters were determined on the basis of a fixed score system. In Group T1, significant differences of clinical parameters could be determined both between the 1st a and 2nd examination dates (p = 0,0042) as well as between the 2nd and 3rd examination dates (p = 0.001). There was a significant improvement in the clinical symptoms based on the clinical score. Conclusively, the study determined a positive effect of the chasteberry-containing preparation corticosal® on the clinical presentation of the horses suffering from Cushingʼs syndrome.

Key words

phytotherapy - horse - equine Cushingʼs disease - chasteberry preparation
 

  • Literatur

  • 1 Adair S, Frank N, Geor R. Guide to insulin resistance & laminitis for equine practitioners. LLOYD Inc.; 2008
    Google Scholar
  • 2 Baumgartner W, Capen CC, Heinrichs M. Immunocytochemical demonstration of proopiomelanocortin-derived peptides in pituitary adenomas of the pars intermedia in horses. Vet Pathol 1990; 27: 419-425
    CrossrefGoogle Scholar
  • 3 Beech J, Boston RC, Lindborg S et al. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction. J Am Vet Med Assoc 2009; 235: 715-722
    CrossrefGoogle Scholar
  • 4 Beech J, Donaldson MT, LaMonte BH et al. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushingʼs disease). J Vet Intern Med 2002; 16: 742-746
    Google Scholar
  • 5 Beech J, Donaldson M, Lindborg S. Comparison of Vitex agnus castus extract and pergolide in the treatment of equine cushing syndrome. AAEP Proceedings 2002; 48: 175-177
    Google Scholar
  • 6 Berger D, Hoberg E, Meier B et al. Pharmacological activities of Vitex agnus-castus extracts in vitro. Phytomedicine 2000; 7: 373-381
    CrossrefGoogle Scholar
  • 7 Breukink HJ, van Garderen E, Kalsbeek HC et al. Equine pituitary neoplasia: a clinical report of 21 cases (1990–1992). Vet Rec 1993; 133: 594-597
    Google Scholar
  • 8 Breukink HJ, Kalsbeek HC, van der Kolk JH et al. Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domest Anim Endocrinol 1995; 12: 35-39
    CrossrefGoogle Scholar
  • 9 Brüns C. Diagnose und Therapieverlauf des equinen Cushing-Syndroms – Rolle des endogenen ACTH [PhD dissertation]. Hannover: 2001
    Google Scholar
  • 10 Copas V, Durham A. Circannual variation in plasma ACTH concentrations in normal horses and ponies and those with pituitary pars intermedia dysfunction. Equine Vet J 2012; 44: 440-443
    CrossrefGoogle Scholar
  • 11 Corazza M, Maccheroni M, Panzani D et al. Equine cushing-like syndrome: diagnosis and therapy in two cases. Vet Res Commun 2004; 28 (Suppl. 01) 377-380
    CrossrefGoogle Scholar
  • 12 Couëtil L, Knoll J, Paradis MR. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. J Vet Intern Med 1996; 10: 1-6
    CrossrefGoogle Scholar
  • 13 Coursen CL, Eberhart SW, Schott HC et al. The Michigan cushingʼ s project. AAEP Proceedings 2001; 47: 22-24
    Google Scholar
  • 14 Divers T. Pergolide and Cyproheptadine: Which medication to choose for treatment of equine cushingʼs disease?. J Equine Vet Sc 2008; 28: 370-371
    Google Scholar
  • 15 Divers TJ, Erb HN, Lamb S et al. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushingʼs disease with cyproheptadine or pergolide. Equine Vet J 2002; 34: 679-685
    Google Scholar
  • 16 Donaldson M, Dybdal N, McFarlane D. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction. Neuroendocrinology 2005; 17: 73-80
    CrossrefGoogle Scholar
  • 17 Elliott SB. Effects of pituitary pars intermedia dysfunction (PPID), season and pasture diet on blood adrenocorticotropic hormone and metabolite concentrations in horses [Master thesis]. Knoxville, Tennessee: University of Tennessee; 2010
    Google Scholar
  • 18 Funk RA, Stewart AJ, Wooldridge AA et al. Seasonal changes in plasma adrenocorticotropic hormone and a-melanocyte-stimulating hormone in response to thyrotropin-releasing hormone in normal, aged horses. J Vet Intern Med 2011; 25: 579-585
    CrossrefGoogle Scholar
  • 19 Goudreau J, Lindley S, Lookingland K. Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary. Neuroendocrinology 1992; 56: 100-105
    CrossrefGoogle Scholar
  • 20 Gorkow C, Jarry H, Leonhardt S et al. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994; 102: 448-454
    Google Scholar
  • 21 Graubner C, Pongratz MC, Wehrli-Eser M. Equine Cushingʼs syndrome: Long-term effect of pergolide therapy. Pferdeheilkunde 2010; 26: 598-603
    Google Scholar
  • 22 Kronfeld D. Insulin resistance predicted by specific proxies. J Equine Vet Sc 2006; 26: 281-284
    Google Scholar
  • 23 McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract 2011; 27: 93-113
    CrossrefGoogle Scholar
  • 24 McGowan C. The role of insulin in endocrinopathic laminitis. J Equine Vet Sc 2008; 28: 603-607
    Google Scholar
  • 25 McGowan T. Aged horse health, management and welfare. [PhD Thesis]. Queensland, Australia: The University of Queensland; 2008
    Google Scholar
  • 26 Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ 2001; 322: 134-137
    CrossrefGoogle Scholar
  • 27 Sommer K. Das Equine Cushing Syndrom: Entwicklung eines ACTH-Bioassays für die Ermittlung des biologisch-immunreaktiven Verhältnisses von endogenem ACTH in equinen Blutproben [PhD dissertation]. Hannover, Germany: 2003
    Google Scholar
  • 28 Schott HC. Pituitary pars intermedia dysfunction: Equine cushingʼs disease. Vet Clin North Am Equine Pract 2002; 18: 237-270
    CrossrefPubMedGoogle Scholar